Frequently Asked Questions

What BPC-157 has been studied for, the three small uncontrolled human reports, the rat and cell work behind the healing claims, and its FDA status.

What CJC-1295 has been studied for: hormone-level trials in healthy adults, a terminated HIV trial and mouse growth data, and why only the DAC form has human data.

Two small topical skin trials in people, and a wound, ligament, lung and brain literature that is animal-only, with the figures each study reported.

What the human trials of glutathione measured — body stores, skin, cystic fibrosis and Parkinson’s — and where the results came up short.

One human efficacy trial (postoperative ileus) that missed its endpoint, one that never posted results, and animal data on bone, muscle and weight.

Obesity, type 2 diabetes and liver fat: what each retatrutide trial measured and found, with the trial behind every figure.

What the randomized trials found in obesity, heart, kidney, liver and joint disease, including the Alzheimer’s trials that failed.

Child growth trials, small adult studies, and what the intranasal data actually tested.

The trials behind each use with their figures, how the dual-hormone action works, and the adverse events the studies reported.

There is no single correct volume — the water sets the concentration, and the concentration sets the syringe units. The reference table converts vial size and volume into units for the trial dose points.

The volume-to-concentration-to-units arithmetic for the 5 mg and 10 mg vials, tabulated against the labelled dose ladder.

The volume-to-concentration-to-units arithmetic for the 10, 30 and 60 mg vials, tabulated against the labelled ladder — including where a vial cannot hold a dose at all.

Why no trial-established dose exists, where the 250 and 500 mcg figures actually came from, and what the species extrapolation behind them assumes.

The doses the retatrutide trials actually administered — Phase 2's 0.5-12 mg range and the Phase 3 TRIUMPH escalation — and why no approved dosing standard exists.

Why there is no such thing as “the semaglutide dose” — four labels, four ceilings and four different missed-dose rules, each attributed to the label it comes from.

The labelled escalation ladder and its ceiling, why the steps are four weeks apart, and the missed-dose rule as the labels actually write it.

Why there is no established BPC-157 dosing frequency — the circulating numbers are convention, and the human evidence is three small uncontrolled reports, none testing a schedule.

Why the pair's frequency splits by half-life — CJC-1295 DAC weekly vs no-DAC CJC and Ipamorelin multiple times daily — with the combination's no-trial caveat.

The once-weekly subcutaneous schedule and every-4-week titration the retatrutide trials used, reported from the profile's cited Phase 2/3 protocols.

The once-weekly injectable schedule (0.25→2.4 mg), the Ozempic/Rybelsus variants, and the every-4-week titration the semaglutide trials and label used.

Why there is no established TB-500 dosing frequency — the loading/maintenance numbers are convention, and the cited studies are mechanism/wound-healing with an animal-estimated half-life.

The once-weekly subcutaneous schedule and every-4-week titration (2.5→15 mg) the tirzepatide trials and FDA label used.

Why there is no characterised human side-effect profile, what “no toxic dose identified” does and does not mean, and the angiogenesis question the literature leaves open.

The one cited IGF-1 LR3 side effect (hypoglycemia) versus what is not established — the analog has no controlled human trials, and the cited sources leave the IGF-1/cancer question open.

Why there is no blend-level side-effect data for KLOW — no trial has studied the four-peptide combination, so side effects are per-component, and each component's human safety data is limited or absent.

The reported rates with the trial behind each, the dysesthesia finding that is specific to retatrutide, and what trial safety data does not tell you about a research-market vial.

The reported rates with the trial behind each, why escalation is when they cluster, and what a label warns about that a trial did not measure.

Why there is no characterized human side-effect profile for thymosin beta-4 / TB-500 — human exposure is two terminated Phase 2 trials, the cited studies are animal wound-healing mechanism, and the tumor question stays theoretical.

The reported rates with the trial behind each, the head-to-head discontinuation figure, and what a boxed warning drawn from rodent data does and does not establish.

What the human record actually holds for oral BPC-157 (one registered trial, no results), what the rat studies showed, and why nasal and sublingual forms have no studies at all.

What the one controlled human trial of topical GHK-Cu found, why it applies to one serum rather than to copper-peptide creams in general, and what is missing for injected, oral and nasal forms.

Why the oral glutathione trials disagree, what the sublingual, inhaled and nasal trials found, and what is and is not known about injected glutathione.

What the one oral NAD+ trial measured, how the precursor pills (NR, NMN) compare, what the injected-NAD+ trial used, and why nasal NAD+ has no study.

What the trials of intranasal oxytocin found, whether a nasal dose reaches the brain, and where the nasal product stands with US and Swiss regulators.

Why the approved PT-141 is an injection only, what the small intranasal trials found, and which nasal papers carry a retraction or an expression of concern.

The three approved tablets against the injection, label by label: how much is absorbed, why the milligram doses differ, what the trials found, and which other GLP-1 drugs come as pills.

What the one human intranasal Semax trial found, what rat studies show about nasal Semax reaching the brain, and where the nasal drops stand with regulators.